Seminar Programme
To apply for seminars, you need your own ID you get after registration. If you haven’t registered yet, please click the following button.

Keynote / Special Seminar

Keynote Seminar

Venue: Seminar Room 6K (East Hall 6)
Capacity: 400 Seats ※Pre Registration required
April 17(Wed.)
6K-01
April 17(Wed.)
9:15-10:15

Current topics regarding regulation of pharmaceuticals in Japan

 

※Opening Ceremony will be held from 9:15am

 

Ministry of Health, Labour and Welfare (MHLW)


Closed

April 18(Thu.)
6K-07
April 18(Thu.)
9:30-11:00
Mr. Tomonori Nakagawa
Ms. Kumiko Numa

Update on ICH Quality Guideline

 

(Speaker)
Mr. Tomonori Nakagawa
Chairperson
ICH Project Quality Group, Quality and Technology Committee
Japan Pharmaceutical Manufacturers Association
(Otsuka Pharmaceutical Co., Ltd.)

 

(Chairman)
Ms. Kumiko Numa
Chairperson
Quality and Technology Committee
Japan Pharmaceutical Manufacturers Association
(Shionogi & Co., Ltd.)


We will share with participants the recently adopted ICH Quality Guidelines for Steps 4 and 5 and their impact on the activities of pharmaceutical companies. It is intended to help promote understanding of these quality guidelines.

Closed

April 19(Fri.)
6K-12
April 19(Fri.)
9:30-10:30
Simultaneous interpretation

Amplifying Impact and Delivering Lasting Value for Patient

Mr. James C. Feliciano
President
AbbVie Japan


FREE

Register

Special Guest Seminar

Venue: Seminar Room 6K (East Hall 6)
Capacity: 400 Seats ※Pre Registration required
April 17(Wed.)
6K-02
April 17(Wed.)
11:00-12:00

AstraZeneca’s challenge as a pioneer company

 

Mr. Takafumi Horii
SVP, President & Representative Director
AstraZeneca K.K.


Closed

April 18(Thu.)
6K-08
April 18(Thu.)
11:30-12:30
Simultaneous interpretation

Takeda R&D Strategic Transformation: Reflections, Successes and Learnings

Mr. Andrew S. Plump
President
Research & Development
Takeda Pharmaceutical Company Limited


Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company. Our intent is to translate science into highly innovative life transforming medicines. We have built an R&D engine focused on enhancing its R&D capabilities, advancing partnerships, and building a robust and diverse pipeline of modalities. Through our R&D strategic transformation and the development of a global ecosystem through partnerships, we will talk about our efforts, our achievements and our vision for the future to improve the quality of innovation using data, digital, and technology.

Closed

April 19(Fri.)
6K-13
April 19(Fri.)
11:30-12:30

Achieving great strides as a global biopharma originating from Japan

 

Mr. Hironoshin Nomura
Executive Officer, Vice President, Chief Financial Officer
Sosei Group Corporation

 


Despite that there are many global pharmaceutical companies and an excellent research base of academia in Japan, no bioppharma has yet been recognized as a global success story.

I will speak about what we have been thinking while struggling to become one such company after a major change in our management structure in 2022, (strategies, initiatives, and behind-the-scenes M&A), and the insights we have gained.

FREE

Register

Special Seminar

Venue: Seminar Room 6K (East Hall 6)
Capacity: 400 Seats ※Pre Registration required
April 17(Wed.)
6K-05
April 17(Wed.)
15:00-16:00
Simultaneous interpretation

Annual Pharma R&D Review: How did the global pipeline develop in 2023?

 

Mr. Ian Haydock
Editor-in-Chief, APAC
Insights
Citeline


This presentation will look at major trends in how the global biopharma R&D pipeline developed in 2023, including number and type of projects, key therapeutic and modality focus areas, company rankings, activity in rare diseases, geographic spread of activity and more.   

Closed

April 18(Thu.)
6K-09
April 18(Thu.)
14:00-16:00
Simultaneous interpretation
Ms. Cynthia Ban
Dr. Rajeev Rehani Budhdev
Ms. Marieke van Daren

<JPTA Conference>

Recent Situations and Challenges in Stable Supply of Active Pharmaceutical Ingredients

Opening remarks by Mr. Ichiro Fujikawa, Chairperson of JAPTA


1. China
Ms. Cynthia Ban, VP, CCCMHPIE(President of Zhejiang Langhua)

2. India
Dr. Rajeev Rehani Budhdev, Executive Vice President & Head– API R&D and Delivery at Dr. Reddy’s Laboratories Limited.

3. Europe
Ms. Marieke van Daren, former board member, representing APIC


Closing remarks by Mr. Hiroshi Nakamura, JAPTA


Recent situations and issues related to the stable supply of APIs in Asia and Europe will be shared, and questions will be raised about those issues.

FREE

Register
April 19(Fri.)
6K-14
April 19(Fri.)
13:00-14:00

How Japan's drug research and development environment remains competitive in the world

 

Mr. Kazuhiko Mori
Senior Managing Director
Japan Pharmaceutical Manufacturers Association


In Japan, "drug loss", the increase in the number of drugs that are approved in Europe and US but unapproved or not even developed in Japan, is recognized as a major problem, and strengthening Japan's drug R&D capabilities is considered an urgent task. On the other hand, the global drug discovery environment is making dramatic progress, as evidenced by the rapid development of breakthrough vaccines and therapeutics during the Covid-19 pandemic starting in 2020.

I will consider what actions are needed to ensure that Japan's drug research and development environment remains competitive in the world in the future.

FREE

Register
6K-15
April 19(Fri.)
14:30-15:15

Living in an era of great intellectual competition
~LCM/DR strategy and pitfalls~

 

Mr. Kaoru SHIMADA

Research Professor 
Collaborative Research for Innovative Drug Discovery
Gifu Pharmaceutical University

Senior Advisor

RaQualia Pharma Inc.


Now in an era of great intellectual competition, we have examples of clever patent strategies by brand-name pharmaceutical companies with taking into consideration product lifecycle management, including drug repositioning, and on the contrary, we have cases where generic companies skillfully exploit deficiencies in patents of brand-name pharmaceutical companies. The intellectual battlefield is reminiscent of the strategies of the Warring States period, and the story unfolds in a way that surpasses even the world of novels and movies. Learning from practical examples, we hope to encourage a further change in the mindset of researchers/developers, leading to ideas for the next generation.

FREE

Register
6K-16
April 19(Fri.)
15:40-16:30
Simultaneous interpretation

The current situation and measures regarding the stable supply of pharmaceuticals

 

Mr. Go Yamamoto
Director, Venture Support Strategy Office
Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Health Policy Bureau
Ministry of Health, Labour and Welfare


The supply shortage of medical drugs, which has expanded since 2021, has not been resolved even after three years, and in addition to the problems of manufacturing and quality management deficiencies and corporate governance that triggered the issue, the impact of drug distribution, industrial structure, inflation, and supply chain challenges has also been pointed out, and the background and causes are becoming more complex. This lecture provides an overview of the current situation analysis of the drug supply shortage and the administrative measures to address it.

FREE

Register

 

Recommended browser is Google Chrome.
Page Top
Loading...